Background: Shufeng Jiedu Capsule (SFJDC), a traditional Chinese medicine, has been used widely as antiviral, antibacterial, antitumor, and anti-inflammatory drugs. Previous studies indicated that some active ingredients of Shufeng Jiedu Capsule, such as resveratrol and quercetin, could suppress hepatocellular carcinoma (HCC) cells through various signaling pathways. However, anti-HCC activity of SFJDC as a complementary medicine remains unexplored. Here, we use a combination of Shufeng Jiedu Capsule and doxorubicin to treat HCC cells and investigated the effects and mechanisms of SFJDC and its ingredientsin vitro.
Methods: In this study, two HCC cell lines, HepG2 and HepG2.2.15, were employed and all cells were separated into seven groups: doxorubicin group, SFJDC group, combination of doxorubicin and SFJDC group, resveratrol group, quercetin group, resveratrol and quercetin group, and control group. Through this research, the cellular functional experiments, such as MTT assay, Hoechst 33,258 staining, would healing assay, and transwell assay, were took to observe the effects of those agents on proliferation, apoptosis, migration and invasion of cells. Then, apoptosis and invasion related genes and proteins were detected by real-time PCR and western blot to illuminate the signaling pathways.
Results: The combination group induced more significant apoptosis and inhibition of migration and invasion by affecting proteins and mRNA of apoptosis, migration, and invasion related elements, such as Bcl-2, Bax, mTOR, and NF-?B. Furthermore, the research suggested SFJDC, as a mixture of a number of ingredients, had stronger activities than particular component or simple mixture of a few components.
Conclusions: SFJDC and its active ingredients could play a role as complementary medicine to increase antitumor effect of doxorubicin by targeting mitochondrial, Akt/mTOR, and NF-?B signaling pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2018.01.163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral traditional Chinese medicine for mild to moderate cases of COVID-19: a network meta-analysis based on RCTs.
J Infect Dev Ctries
November 2024
Department of Oncology, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730030, China.
Introduction: This systemic review examines the effectiveness and safety of combining traditional Chinese medicine with standard therapy in the treatment of mild to moderate cases of coronavirus disease 2019 (COVID-19).
Methodology: We retrieved articles from PubMed, Web of Science, Cochrane, Embase, China National Knowledge Infrastructure (CNKI), Wanfang, Weipi (VIP), and China Biology Medicine disc (CBM). The deadline for retrieval was 20 August 2022, and it was updated on 1 July 2023.
Mechanisms of Shufeng Jiedu Capsule in treating bacterial pneumonia based on network pharmacology and experimental verification.
Chin Herb Med
October 2024
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100029, China.
Article Synopsis
- The study aimed to explore how Shufeng Jiedu Capsule (SFJD) treats bacterial pneumonia through network pharmacology and experimental methods.
- Researchers found 172 active components in SFJD and built a network connecting these components with target genes related to bacterial pneumonia, highlighting its effects on the IL-17 and JAK/STAT signaling pathways.
- SFJD showed promising results by reducing mortality in mouse models of pneumonia and decreasing harmful inflammatory markers, indicating its potential as a treatment for bacterial pneumonia.*
Effectiveness of seven oral traditional Chinese medicines against mild or moderate COVID-19: An updated systematic review and network meta-analysis.
Heliyon
August 2024
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, 100730, PR China.
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the outbreak of COVID-19 in Wuhan, China. As a highly infectious epidemic, SARS-CoV-2 rapidly evolves. Presently, COVID-19 coexists with humans, mainly with mild or moderate disease.
View Article and Find Full Text PDFShuangdan Jiedu Decoction improved LPS-induced acute lung injury by regulating both cGAS-STING pathway and inflammasome.
J Ethnopharmacol
January 2025
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, PR China; Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, PR China; State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, 100700, PR China; National Key Laboratory of Kidney Diseases, Beijing 100005, PR China. Electronic address:
Ethnopharmacological Relevance: Shuangdan Jiedu Decoction (SJD) is a formula composed of six Chinese herbs with heat-removing and detoxifying, antibacterial, and anti-inflammatory effects, which is clinically used in the therapy of various inflammatory diseases of the lungs including COVID-19, but the therapeutic material basis of its action as well as its molecular mechanism are still unclear.
Aim Of The Study: The study attempted to determine the therapeutic effect of SJD on LPS-induced acute lung injury (ALI), as well as to investigate its mechanism of action and assess its therapeutic potential for the cure of inflammation-related diseases in the clinical setting.
Materials And Methods: We established an ALI model by tracheal drip LPS, and after the administration of SJD, we collected the bronchoalveolar lavage fluid (BALF) and lung tissues of mice and examined the expression of inflammatory factors in them.
Shufeng Jiedu capsule alleviates influenza A (H1N1) virus induced acute lung injury by regulating the lung inflammatory microenvironment.
Heliyon
June 2024
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100025, China.
Background: Death caused by respiratory tract infection is one of the leading causes of death in the world today. Shufeng Jiedu Capsule (SFJDC) is a traditional Chinese medicine that has been widely used clinically for coronavirus disease 2019 (COVID-19), H1N1 influenza virus pneumonia and other diseases. Its pharmacological effect is to inhibit inflammation and improve the body's ability to clear viruses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!